Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement
- 1 October 2007
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 110 (7) , 2296-2301
Abstract
Enzyme replacement therapy (ERT) with imiglucerase reduces hepatosplenomegaly and improves hematologic parameters in Gaucher disease type 1 within 6-24 months. Miglustat reduces organomegaly, improves hematologic parameters, and reverses bone marrow infiltration. This trial evaluates miglustat in patients clinically stable on ERT. Tolerability of miglustat and imiglucerase, alone and in combination, pharmacokinetic profile, organ reduction, and chitotriosidase activity were assessed. Thirty-six patients stable on imiglucerase were randomized into this phase II, open-label trial. Statistically significant changes from baseline were assessed (paired t test) on primary objectives with secondary analyses on biochemical and safety parameters. Liver and spleen volume were unchanged in switched patients. No significant differences were seen between groups regarding mean change in hemoglobin. Mean change in platelet counts was only significant between miglustat and imiglucerase groups (P = .035). Chitotriosidase activity remained stable. In trial extension, clinical endpoints were generally maintained. Miglustat was well tolerated alone or in combination. Miglustat's safety profile was consistent with previous trials; moreover, no new cases of peripheral neuropathy were observed. Gaucher disease type 1 (GD1) parameters were stable in most switched patients. Combination therapy did not show benefit. Findings suggest miglustat could be an effective maintenance therapy in stabilized patients with GD1.Keywords
This publication has 30 references indexed in Scilit:
- An open-label, noncomparative study of miglustat in type I Gaucher disease: Efficacy and tolerability over 24 months of treatmentClinical Therapeutics, 2005
- Gaucher disease type 1: Revised recommendations on evaluations and monitoring for adult patientsSeminars in Hematology, 2004
- The role of the iminosugar N‐butyldeoxynojirimycin (miglustat) in the management of type I (non‐neuronopathic) Gaucher disease: A position statementJournal of Inherited Metabolic Disease, 2003
- Reply to weinrebBritish Journal of Haematology, 2001
- Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesisThe Lancet, 2000
- Testing the Equivalence of Translations of Widely Used Response Choice LabelsJournal of Clinical Epidemiology, 1998
- Echocardiographic assessment of pulmonary hypertension in Gaucher's diseaseThe Lancet, 1998
- Treatment of Gaucher disease with an enzyme inhibitorGlycoconjugate Journal, 1996
- Replacement Therapy for Inherited Enzyme Deficiency — Macrophage-Targeted Glucocerebrosidase for Gaucher's DiseaseNew England Journal of Medicine, 1991
- Minimization: A new method of assigning patients to treatment and control groupsClinical Pharmacology & Therapeutics, 1974